National
Top 10 national news stories of 2023
Pride stunt gone wrong, state houses attack, and more
It was an alarming year for queer Americans as state legislatures took aim at everything from gender-affirming care for transgender people to banning books with queer themes. Here are the Blade’s staff picks for the top 10 stories of 2023.
#10 Pride at the White House
The Biden-Harris administration in June hosted the largest Pride celebration ever held on White House grounds. Thousands gathered on the South Lawn to hear the president reaffirm his commitment to the LGBTQ community, decry the introduction and passage of legislation targeting queer people, and outline new actions the administration would take to tackle issues from bias-motivated threats and violence to youth homelessness. After the event, right-wing activists drew attention to a trans activist attendee’s topless TikTok video, which prompted a rebuke from the White House. Press Secretary Karine Jean-Pierre said the “influencer” would not be invited back.
#9 Off-year elections spell victory for Dems, poor showing for Moms for Liberty
Polls show that Democrats largely over-performed in off-year elections that were held in November 2023, with Democratic hopefuls in competitive races securing decisive victories up and down the ballot – from the gubernatorial race in Kentucky to school board contests in states across the country. Moms for Liberty, an anti-LGBTQ right-wing organization considered an extremist group by the Southern Poverty Law Center, backed 139 candidates in school board races who vowed to oppose books, materials, and classroom discussion or instruction on LGBTQ matters or those concerning racial justice. Just over a third of those candidates – 50 – won.
#8 FDA finalizes new, inclusive blood donation guidelines
Gay and bisexual men who have sex with men have been prohibited from donating blood for decades since the discovery of AIDS, with the U.S. Food and Drug Administration narrowing its restrictions only twice since the 1980s. Revisiting blood donation guidelines has been a major priority for the Biden-Harris administration, and the FDA’s decision this year to take a major step away from the discriminatory ban was lauded by LGBTQ groups – some of which vowed that they would continue, in the words of GLAAD President Sarah Kate Ellis, “advocating for the FDA to lift all restrictions against qualified LGBTQ blood donor candidates.”
#7 Battle over the Republican speakership
U.S. Rep. Kevin McCarthy (R-Calif.) narrowly secured the votes to become speaker in January and only after a historic 15 ballots were cast. He was summarily ousted by a small group of ultraconservative members before the end of the year, throwing the House into turmoil as the Republican conference flailed for weeks without a speaker until they united around U.S. Rep. Mike Johnson (R-La.). Johnson is an anti-LGBTQ far-right Christian fundamentalist who has advocated for the reinstatement of sodomy laws and nurtured close ties with the most extreme figures on the religious right.
#6 Pelosi steps down from leadership and is interviewed by the Blade
In January, just after the end of her tenure as one of the most celebrated and accomplished House speakers, U.S. Rep. Nancy Pelosi (D-Calif.) sat down with the Washington Blade in her office for an interview about her work advancing the social, legal, and political equality of LGBTQ people in America. From her first speech on the House floor in 1987 demanding congressional action on AIDS to her leadership in 2022 passing the Respect for Marriage Act, the California Democrat has been at the forefront of the battle for LGBTQ rights while also blazing a trail for women to serve in the highest levels of American politics and government.
#5 George Santos drama
Before his time in Washington had even begun, the first out gay Republican elected to Congress was revealed to be a total fraud with respect to matters that ranged from the frivolous (claims of collegiate athletic prowess) to the legally actionable (pilfering campaign donations to buy Ferragamo loafers and content on OnlyFans). At first, House Republican leadership stood by Santos through the torrent of unflattering news coverage, mindful of the party’s narrow majority control of the lower chamber. Eventually, however, lawmakers were handed a damning report by the bipartisan House Ethics Committee and made the unprecedented move of booting him out of office.
#4 303 Creative v. Elenis
The Alliance Defending Freedom, which is deemed an anti-LGBTQ hate group by the Southern Poverty Law Center, represented a Colorado website designer who, though she had never been asked to provide services in connection with a same-sex wedding, feared that she would be prohibited from refusing such a request because of the state’s LGBTQ inclusive nondiscrimination statute. The U.S. Supreme Court not only agreed to review the case, concluding that the business owner had standing to sue, but ruled in her favor – delivering a blow to LGBTQ rights in a decision weakening the court’s precedent on marriage equality.
#3 Anti-trans policies to figure prominently in Trump v. Biden rematch
Former President Trump has maintained a decisive lead over the rest of the Republican presidential primary field since the start of 2023, which has widened considerably since the summer. Announcing his plans to run again in January, Trump outlined a plan of attack against transgender Americans, including policy proposals targeting access to gender affirming care and appeals for congressional Republicans to define gender as immutable and assigned at birth. President Biden, meanwhile, has no meaningful competition from other Democrats leading into 2024, and has vowed to protect and defend transgender Americans while taking steps to shore up protections for the community during his time in office.
#2 Major companies fend off right-wing attacks
The year 2023 saw publicly traded corporations like Target and Anheuser-Busch InBev take financial hits after their outreach to LGBTQ communities inspired reactionary right-wing backlash. The companies’ responses, in turn, ignited criticism from LGBTQ customers who felt abandoned by their decisions to, for instance, scale back on next year’s Pride collections. Transgender influencer Dylan Mulvaney partnered with Bud Light for a social media promotion in April – consisting of a single video posted on her Instagram page – and it was only in December that right-wing activist and musician Kid Rock dropped his boycott against the company, having made headlines months earlier by mowing down cases of the product with an assault rifle.
#1 State of emergency for LGBTQ people in America
State legislatures across the country introduced more than 500 bills targeting the LGBTQ community in 2023, passing 75 in 23 states. Most are restrictions on medically necessary healthcare interventions for transgender minors, treatments that are backed by every scientific and medical society with relevant clinical expertise. Others target trans student athletes, restrict bathroom and locker room access, or prohibit schools from any discussion or instruction on matters of sexual orientation and gender identity. LGBTQ people and their families have become refugees in their own country. And the Human Rights Campaign declared a state of emergency for the first time ever.
Honorable mention: Blade uncovers Trevor Project scandals
In July, the Washington Blade broke an explosive exposé concerning one of the country’s largest LGBTQ advocacy organizations, the Trevor Project, which provides crisis intervention services to LGBTQ youth. The story revealed financial woes, raised questions about the possible mismanagement of millions of dollars in funds, and pointed to staff dissension — including over management’s alleged union-busting efforts.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
The White House
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
Trans former assistant health secretary’s name changed on official portrait
Democracy Forward, a national legal organization that works to advance democracy and social progress through litigation, policy and public education, and regulatory engagement, filed a lawsuit Friday in federal court seeking to compel the U.S. Department of Health and Human Services to release information related to the alteration of former Assistant Secretary for Health Adm. Rachel Levine’s official portrait caption.
The lawsuit comes in response to the slow pace of HHS’s handling of multiple Freedom of Information Act requests — requests that federal law requires agencies to respond to within 20 working days. While responses can take longer due to backlogs, high request volumes, or the need for extensive searches or consultations, Democracy Forward says HHS has failed to provide any substantive response.
Democracy Forward’s four unanswered FOIA requests, and the subsequent lawsuit against HHS, come days after someone in the Trump-Vance administration changed Levine’s official portrait in the Hubert H. Humphrey Building to display her deadname — the name she used before transitioning and has not used since 2011.
According to Democracy Forward, HHS “refused to release any records related to its morally wrong and offensive effort to alter former Assistant Secretary for Health Admiral Rachel Levine’s official portrait caption.” Levine was the highest-ranking openly transgender government official in U.S. history and served as assistant secretary for health and as an admiral in the U.S. Public Health Service Commissioned Corps from 2021 to 2025.
Democracy Forward President Skye Perryman spoke about the need to hold the Trump-Vance administration accountable for every official action, especially those that harm some of the most targeted Americans, including trans people.
“The question every American should be asking remains: what is the Trump-Vance administration hiding? For an administration that touts its anti-transgender animus and behavior so publicly, its stonewalling and silence when it comes to the people’s right to see public records about who was behind this decision is deafening,” Perryman said.
“The government’s obligation of transparency doesn’t disappear because the information sought relates to a trailblazing former federal official who is transgender. It’s not complicated — the public is entitled to know who is making decisions — especially decisions that seek to alter facts and reality, erase the identity of a person, and affect the nation’s commitment to civil rights and human dignity.”
“HHS’s refusal to respond to these lawful requests raises more serious concerns about transparency and accountability,” Perryman added. “The public has every right to demand answers — to know who is behind this hateful act — and we are going to court to get them.”
The lawsuit also raises questions about whether the alteration violated federal accuracy and privacy requirements governing Levine’s name, and whether the agency improperly classified the change as an “excepted activity” during a lapse in appropriations. By failing to make any determination or produce any records, Democracy Forward argues, HHS has violated its obligations under federal law.
The case, Democracy Forward Foundation v. U.S. Department of Health and Human Services, was filed in the U.S. District Court for the District of Columbia. The legal team includes Anisha Hindocha, Daniel McGrath, and Robin Thurston.
The Washington Blade reached out to HHS, but has not received any comment.
The lawsuit and four FOIA requests are below:
‘Dogs of Venice’ looks at love lost and rediscovered
A Wider Bridge to close
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
Rehoboth’s Blue Moon is for sale but owners aim to keep it in gay-friendly hands
Comings & Goings
LGBTQ Democrats say they’re ready to fight to win in 2026
Brian Footer suspends campaign for Ward 1 D.C. Council seat
Lighting candles in a time of exhaustion
Why queer spaces often fail South Asian women
